NCT04447118 2025-12-19
PYRAMID-1
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
Clinical Trials
7 trialsNCT03588091 2025-08-22
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT05424835 2025-08-22
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT03863223 2022-11-23
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02973737 2022-10-25
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03980054 2021-05-24
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03080805 2020-06-18
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown